Aliciak Morgans News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Darolutamide-Related PSA Response in nmCRPC Predicts Radiologic Progression Risk

PSA levels in darolutamide recipients are associated with risk for progression of nonmetastatic castration-resistant prostate cancer (nmCRPC).

United statesAliciak morgansDana farber cancer center

SUO 2023: Androgen Receptor Agonist versus Antagonist: Cardiac Morbidity

SUO 2023: Androgen Receptor Agonist versus Antagonist: Cardiac Morbidity
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesDana farber cancer instituteKaplan meierJ cardiovasc pharmacotherAlicia morgansAliciak morgansSociety of urologic oncologyDepartment of medicineSurvivorship program at dana farber cancer instituteUniversity of torontoUrologic oncologyFollicle stimulating hormoneNew england journalAssociate professorMedical directorSurvivorship program

ESMO 2023: Tolerance and Long-Term Side-Effects

ESMO 2023: Tolerance and Long-Term Side-Effects
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesDana farber cancer instituteAlicia morgansAliciak morgansEuropean society of medical oncologySurvivorship program at dana farber cancer instituteUniversity of torontoDepartment of medicineSociety of urologic oncologyMedical oncologyAnnual congressAssociate professorMedical directorSurvivorship programMassachusetts general hospitalUrologic oncology

JNM Releases Consensus on Lu-177 PSMA-617 Therapy Use

JNM Releases Consensus on Lu-177 PSMA-617 Therapy Use
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesMemorial sloan kettering cancer centerNew yorkUniversity of minnesotaSan franciscoUniversity of california san franciscoDana farber cancer instituteUniversity of washingtonOliver sartorHeather jaceneAmir iravaniScottt tagawaAliciak morgansMary ellen taplinMichaelj morrisLisa bodei

Darolutamide Has Advantages Over Other ARIs for nmCRPC, Real-World Data Show

A real-world study compared discontinuation and progression among androgen receptor inhibitors for castration-resistant prostate cancer (nmCRPC).

United statesDana farber cancer instituteAliciak morgansAmerican society of clinical oncologyAmerican societyClinical oncologyPrecision point specialty